Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22023973 | 0.87 | KMT2A (0.40) | KMT2AMAPK1MEN1TDP1L3MBTL1 | |
| SCHEMBL1104678 | 0.82 | KMT2A (0.46) | KMT2AMAPK1MEN1TDP1L3MBTL1 | |
| SCHEMBL23597829 | 0.81 | ALDH1A1 (0.39) | KMT2AMAPK1MEN1TDP1L3MBTL1 | |
| SCHEMBL6002955 | 0.79 | KMT2A (0.44) | KMT2AMAPK1MEN1TDP1L3MBTL1 | |
| SCHEMBL21577670 | 0.76 | KMT2A (0.35) | KMT2AMAPK1MEN1TDP1L3MBTL1 | |
| SCHEMBL21941492 | 0.74 | KMT2A (0.33) | KMT2AMAPK1MEN1TDP1L3MBTL1 | |
| SCHEMBL21236222 | 0.74 | ALDH1A1 (0.36) | KMT2AMAPK1MEN1TDP1L3MBTL1 | |
| SCHEMBL21846090 | 0.74 | KDM4E (0.43) | KMT2AMEN1TDP1ALDH1A1GAA | |
| SCHEMBL19177266 | 0.72 | KDM4E (0.46) | KMT2AMEN1ALDH1A1MAPTPOLB | |
| SCHEMBL762080 | 0.71 | TP53 (0.47) | KMT2AMAPK1MEN1TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11793806-B2 | Pyruvate kinase activators for use in therapy | AGIOS PHARMACEUTICALS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-20 | — | — | US | disclosed |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20210292320-A1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2021-09-23 | — | — | US | disclosed |
| US-10988448-B2 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20190345109-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. | 2019-11-14 | — | — | US | disclosed |
| US-10029987-B2 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-9980961-B2 | Pyruvate kinase activators for use in therapy | AGIOS PHARMACEUTICALS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170290825-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY | AGIOS PHARMACEUTICALS, INC. | 2017-10-12 | — | — | US | disclosed |
| US-20170183311-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | KMT2A 1069/4885MAPK1 4389/4885MEN1 4128/4885 |
| US-11793806-B2 | Pyruvate kinase activators for use in therapy | PCK1, PDK3, PDK2 | KMT2A 1401/4885MAPK1 1175/4885MEN1 3741/4885 |
| US-20210292320-A1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS | HAVCR2, HDGF, HCCS | KMT2A 3422/4885MAPK1 1141/4885MEN1 3913/4885 |
| US-10029987-B2 | Therapeutic compounds and compositions | PDK1, PDK2, PDK3 | KMT2A 751/4885MAPK1 1197/4885MEN1 3010/4885 |
| US-20170183311-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PDK2, PDK3 | KMT2A 751/4885MAPK1 1197/4885MEN1 3010/4885 |
| US-10988448-B2 | Therapeutic compounds and compositions | PDK1, PDK2, PDK3 | KMT2A 751/4885MAPK1 1197/4885MEN1 3010/4885 |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | KMT2A 1069/4885MAPK1 4389/4885MEN1 4128/4885 |
| US-20190345109-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PDK2, PDK3 | KMT2A 751/4885MAPK1 1197/4885MEN1 3010/4885 |
| US-20170290825-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY | PCK1, PDK3, PDK2 | KMT2A 1401/4885MAPK1 1175/4885MEN1 3741/4885 |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | KMT2A 3369/4885MAPK1 1118/4885MEN1 3467/4885 |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | KMT2A 3369/4885MAPK1 1118/4885MEN1 3467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.